Market Cap 432.45M
Revenue (ttm) 31.08M
Net Income (ttm) -200.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -644.79%
Debt to Equity Ratio 0.43
Volume 1,414,600
Avg Vol 3,762,812
Day's Range N/A - N/A
Shares Out 363.40M
Stochastic %K 77%
Beta 1.17
Analysts Sell
Price Target $2.75

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 863 3000
Fax: 281 863 8088
Address:
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States
SPARTANWHITE22
SPARTANWHITE22 Aug. 24 at 7:37 PM
$LXRX LX 9211 is targeted for Nerve pain...Not Somatic pain. The often prescribed Nerontin AKA Gabapentin is currently the go to drug for nerve pain.....after Shingles or for Diabetic Neuropathy... Incredibly they are not even sure how it works. The best guess is that it lowers circulating Glutamate levels in the body..a known nerve cell irritant. Any new viable entry to treat this indication would be welcome and profitable.
0 · Reply
TH3_PR0F1T
TH3_PR0F1T Aug. 24 at 7:28 PM
$LXRX I believe we are going to see accumulation taking place over the next couple of weeks. It nice to see the shorts steering clear as everyone is expecting a deal.
0 · Reply
gucag006
gucag006 Aug. 24 at 11:31 AM
$LXRX LX9211 animal trial, Part 2: Safety and CNS penetration: The trials confirmed that LX9211 was able to cross the blood-brain barrier (exhibited central nervous system penetration) and had an acceptable safety and toxicity profile in preclinical species. Activity in spinal cord: In rat models, LX9211's efficacy was correlated with target engagement in the spinal cord. Lack of effect on acute pain: Interestingly, animal models did not show an effect of AAK1 inhibition on acute pain perception, suggesting its action is specific to neuropathic pain pathways. Spasticity: Later preclinical models also showed that LX9211 had an effect on reducing spasticity. Beyond preclinical studies The successful outcome of these animal trials supported the progression of LX9211 into human clinical trials. It has since completed Phase 1 studies and undergone several Phase 2 trials for diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia.
2 · Reply
gucag006
gucag006 Aug. 24 at 11:26 AM
$LXRX From Google Search, Pary 1: Lexicon Pharmaceuticals conducted animal trials (preclinical studies) with LX9211 in rodents, primarily rats and mice. These studies provided the basis for the drug's advancement into human clinical trials for neuropathic pain. Animal trials in rodents Target identification: Early research identified adaptor-associated kinase 1 (AAK1) as a promising non-opioid target for neuropathic pain using knockout mice, which lack the AAK1 gene. Mechanism of action: LX9211 was shown to be a potent, selective, and orally delivered inhibitor of the AAK1 enzyme. AAK1 inhibition, through small-molecule inhibition in animal models, was shown to reduce pain-related behaviors. Efficacy in pain models: The preclinical studies demonstrated that LX9211 reduced pain behavior in various neuropathic pain models in rodents. This was achieved without affecting opioid pathways, suggesting a non-addictive mechanism.
0 · Reply
Marta22
Marta22 Aug. 23 at 5:43 PM
$LXRX Nerves transmit signals (such as pain) using neurotransmitters (these are like “letters” that carry information from one cell to another). AAK1 controls the recycling of receptors, meaning it decides when and how these “mailboxes” for the letters return to the surface of the cell. If AAK1 is overactive, nerve cells can become hypersensitive, which makes it easier for them to send and receive pain signals. When we block AAK1 (as pilavapadin does), we reduce the intensity of pain signals that reach the brain. It’s a bit like turning down the volume on speakers — the signal is still there, but it’s less bothersome. Importantly, this mechanism has nothing to do with opioids (such as morphine or codeine), so it does not cause addiction. AAK1 is a regulator of pain transmission in nerves. Pilavapadin blocks it, which “cuts off part of the cables” transmitting pain, but without damaging the entire nervous system.
2 · Reply
Marta22
Marta22 Aug. 23 at 5:18 PM
$LXRX Lexicon Pharmaceuticals is preparing to initiate Phase III trials of pilavapadin for the treatment of diabetic peripheral neuropathic pain and continues to maintain its goal of starting this stage in 2025. Following the completion of the Phase IIb PROGRESS study, the company announced that full results will be presented at a medical conference in September 2025. This event is expected to be pivotal, as it will serve as the basis for an “end of Phase II” meeting with the FDA, which will formally open the path toward launching the next phase of development. Company leadership has emphasized that the timeline will also depend on ongoing discussions with potential strategic partners. This means the most likely scenario is for Phase III to begin in late 2025, although if negotiations or regulatory processes are prolonged, the trial could be pushed into early 2026.
1 · Reply
Beebomb
Beebomb Aug. 23 at 5:02 PM
$LXRX I would like for someone with a real understanding of the subject to offer a summary of the Pilavadapin results from animal studies. Everyone knows that is not a surefire predictor of parallel results in humans but, from my limited understanding, those results suggested strongly a physiological pathway that could produce meaningful results.
1 · Reply
KurwaMac
KurwaMac Aug. 23 at 4:25 PM
$LXRX I need a refresh, when were they planning on starting phase 3?
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 23 at 12:56 PM
$LXRX September will be a great month us!!!
0 · Reply
BullriderNkg
BullriderNkg Aug. 23 at 11:57 AM
$LXRX If management is fairly precise, everyone should know, who our Pilavapadin partner is in 5 weeks. End of Q3. Any guesstimates on stock price upon announcement?
1 · Reply
Latest News on LXRX
Top 2 Health Care Stocks That May Crash This Month

Apr 25, 2025, 9:00 AM EDT - 4 months ago

Top 2 Health Care Stocks That May Crash This Month


Lexicon Appoints Scott Coiante as Chief Financial Officer

Jan 2, 2025, 8:00 AM EST - 8 months ago

Lexicon Appoints Scott Coiante as Chief Financial Officer


US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Dec 20, 2024, 4:46 PM EST - 8 months ago

US FDA declines to approve Lexicon Pharma's add-on diabetes drug


Lexicon Appoints Ivan H. Cheung to Board of Directors

Nov 20, 2024, 4:05 PM EST - 9 months ago

Lexicon Appoints Ivan H. Cheung to Board of Directors


SPARTANWHITE22
SPARTANWHITE22 Aug. 24 at 7:37 PM
$LXRX LX 9211 is targeted for Nerve pain...Not Somatic pain. The often prescribed Nerontin AKA Gabapentin is currently the go to drug for nerve pain.....after Shingles or for Diabetic Neuropathy... Incredibly they are not even sure how it works. The best guess is that it lowers circulating Glutamate levels in the body..a known nerve cell irritant. Any new viable entry to treat this indication would be welcome and profitable.
0 · Reply
TH3_PR0F1T
TH3_PR0F1T Aug. 24 at 7:28 PM
$LXRX I believe we are going to see accumulation taking place over the next couple of weeks. It nice to see the shorts steering clear as everyone is expecting a deal.
0 · Reply
gucag006
gucag006 Aug. 24 at 11:31 AM
$LXRX LX9211 animal trial, Part 2: Safety and CNS penetration: The trials confirmed that LX9211 was able to cross the blood-brain barrier (exhibited central nervous system penetration) and had an acceptable safety and toxicity profile in preclinical species. Activity in spinal cord: In rat models, LX9211's efficacy was correlated with target engagement in the spinal cord. Lack of effect on acute pain: Interestingly, animal models did not show an effect of AAK1 inhibition on acute pain perception, suggesting its action is specific to neuropathic pain pathways. Spasticity: Later preclinical models also showed that LX9211 had an effect on reducing spasticity. Beyond preclinical studies The successful outcome of these animal trials supported the progression of LX9211 into human clinical trials. It has since completed Phase 1 studies and undergone several Phase 2 trials for diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia.
2 · Reply
gucag006
gucag006 Aug. 24 at 11:26 AM
$LXRX From Google Search, Pary 1: Lexicon Pharmaceuticals conducted animal trials (preclinical studies) with LX9211 in rodents, primarily rats and mice. These studies provided the basis for the drug's advancement into human clinical trials for neuropathic pain. Animal trials in rodents Target identification: Early research identified adaptor-associated kinase 1 (AAK1) as a promising non-opioid target for neuropathic pain using knockout mice, which lack the AAK1 gene. Mechanism of action: LX9211 was shown to be a potent, selective, and orally delivered inhibitor of the AAK1 enzyme. AAK1 inhibition, through small-molecule inhibition in animal models, was shown to reduce pain-related behaviors. Efficacy in pain models: The preclinical studies demonstrated that LX9211 reduced pain behavior in various neuropathic pain models in rodents. This was achieved without affecting opioid pathways, suggesting a non-addictive mechanism.
0 · Reply
Marta22
Marta22 Aug. 23 at 5:43 PM
$LXRX Nerves transmit signals (such as pain) using neurotransmitters (these are like “letters” that carry information from one cell to another). AAK1 controls the recycling of receptors, meaning it decides when and how these “mailboxes” for the letters return to the surface of the cell. If AAK1 is overactive, nerve cells can become hypersensitive, which makes it easier for them to send and receive pain signals. When we block AAK1 (as pilavapadin does), we reduce the intensity of pain signals that reach the brain. It’s a bit like turning down the volume on speakers — the signal is still there, but it’s less bothersome. Importantly, this mechanism has nothing to do with opioids (such as morphine or codeine), so it does not cause addiction. AAK1 is a regulator of pain transmission in nerves. Pilavapadin blocks it, which “cuts off part of the cables” transmitting pain, but without damaging the entire nervous system.
2 · Reply
Marta22
Marta22 Aug. 23 at 5:18 PM
$LXRX Lexicon Pharmaceuticals is preparing to initiate Phase III trials of pilavapadin for the treatment of diabetic peripheral neuropathic pain and continues to maintain its goal of starting this stage in 2025. Following the completion of the Phase IIb PROGRESS study, the company announced that full results will be presented at a medical conference in September 2025. This event is expected to be pivotal, as it will serve as the basis for an “end of Phase II” meeting with the FDA, which will formally open the path toward launching the next phase of development. Company leadership has emphasized that the timeline will also depend on ongoing discussions with potential strategic partners. This means the most likely scenario is for Phase III to begin in late 2025, although if negotiations or regulatory processes are prolonged, the trial could be pushed into early 2026.
1 · Reply
Beebomb
Beebomb Aug. 23 at 5:02 PM
$LXRX I would like for someone with a real understanding of the subject to offer a summary of the Pilavadapin results from animal studies. Everyone knows that is not a surefire predictor of parallel results in humans but, from my limited understanding, those results suggested strongly a physiological pathway that could produce meaningful results.
1 · Reply
KurwaMac
KurwaMac Aug. 23 at 4:25 PM
$LXRX I need a refresh, when were they planning on starting phase 3?
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 23 at 12:56 PM
$LXRX September will be a great month us!!!
0 · Reply
BullriderNkg
BullriderNkg Aug. 23 at 11:57 AM
$LXRX If management is fairly precise, everyone should know, who our Pilavapadin partner is in 5 weeks. End of Q3. Any guesstimates on stock price upon announcement?
1 · Reply
TH3_PR0F1T
TH3_PR0F1T Aug. 23 at 11:56 AM
0 · Reply
Marta22
Marta22 Aug. 23 at 10:35 AM
$LXRX Of course, pilavapadin's real impact on the opioid epidemic depends on the success of further studies, regulatory approval, and the availability of this drug in clinical practice. Any reduction in opioid exposure in the clinical population reduces the risk of tolerance, addiction, and subsequent diversion to the illicit market. The inclusion of pilavapadine in guidelines and medication formularies (upon approval) will give clinicians a viable "nonopioid first" tool before resorting to opioids. Potential expansion of indications to other neuropathies will be important over time. Good luck to all those on the long haul.
0 · Reply
Marta22
Marta22 Aug. 23 at 10:35 AM
$LXRX It is worth focusing on the progress in pilavapadin, maybe the partnership will concern this drug Pilavapadin is a non-opioid pain reliever. If proven effective and safe, it could reduce the need for opioids such as fentanyl in people suffering from chronic neuropathic pain, especially those with diabetes. Reducing opioid prescriptions is a key element of the strategy to reduce the availability of these medications and the risk of addiction. When patients have access to effective therapy that does not carry the risk of addiction, the number of people resorting to opioids decreases, reducing the risk of both addiction and overdose. The current fight against the opioid epidemic is based, among other things, on harm reduction and the promotion of effective alternatives to pain management. Therapy with a drug like pilavapadin fits perfectly into this philosophy.
0 · Reply
hmanonline
hmanonline Aug. 23 at 6:50 AM
$LXRX could be a positive chain reaction to lexicon coming of novo moves off something soon
0 · Reply
Jbjb90
Jbjb90 Aug. 23 at 1:02 AM
$LXRX im going to reshare a reshare on some inception shit, if Exton is this confident in the Novo pill deal, we should continue to hit milestones and in return get the reward, its up to a billion including royalties, a great find on what Exton said 💪
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 23 at 12:30 AM
$LXRX Excellent.
0 · Reply
Thekareemofthecrop
Thekareemofthecrop Aug. 23 at 12:21 AM
0 · Reply
Zzassaz
Zzassaz Aug. 22 at 11:31 PM
$LXRX this wouldn’t change too much until the news gets released. I’m waiting….
0 · Reply
Jbjb90
Jbjb90 Aug. 22 at 9:45 PM
$LXRX didnt hit two mil volume any day this week, i expect more of the same til news, i was in the mountains this morning with no reception from before open to pretty much the close, i half expected with my luck the news would drop and id miss it and be late the the party 😂 I think its looking like that September conference is our next legit shot at news and a slow churn until then, maybe we get s rate cut and partnership news in September and this hits the moon 🤞
0 · Reply
beachbroke
beachbroke Aug. 22 at 9:38 PM
$LXRX going to start calling it green fridays if it keeps this up.
0 · Reply
alcat1973
alcat1973 Aug. 22 at 8:43 PM
$LXRX Hey, not 1.25, but I"ll take it. Green is green.
0 · Reply
Thekareemofthecrop
Thekareemofthecrop Aug. 22 at 6:49 PM
$LXRX Mike’s comment.
3 · Reply